News articles about Intrexon (NYSE:XON) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intrexon earned a news impact score of 0.17 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.5897457678462 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Turning Up the Heat on Shares of Intrexon Corporation (NYSE:XON) – SCY News (scynews.com)
- Quotidian Technical Highlights on Selected Biotech Stocks — Voyager Therapeutics, Cambrex, Emergent BioSolutions … – PR Newswire (press release) (prnewswire.com)
- Intrexon Announces Proposed Public Offering of Common Stock – PR Newswire (press release) (prnewswire.com)
- ANI Pharmaceuticals (ANIP) & Intrexon (XON) Head-To-Head Analysis (americanbankingnews.com)
Several equities research analysts have recently issued reports on the company. ValuEngine lowered Intrexon from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research lowered Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. JMP Securities reiterated an “outperform” rating and set a $42.00 price target on shares of Intrexon in a report on Thursday, October 5th. Stifel Nicolaus lifted their price target on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a report on Friday, November 10th. Finally, Northland Securities reiterated a “buy” rating and set a $21.00 price target on shares of Intrexon in a report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $38.50.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. analysts predict that Intrexon will post -1.06 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intrexon (XON) Stock Price” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://baseballnewssource.com/markets/intrexon-xon-receives-daily-media-impact-score-of-0-17/1822123.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.